FDA cracking down telehealth companies On March 2, the FDA announced it sent 30 letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites
besides this, shortages and supply chain difficulties by pharma companies with constrained production capacity and a risk of counterfeit products in the market
What weve found is that virtual care solutions play a crucial role in supporting patients looking to continue their GLP-1 medications, even in times of supply challenges
If you don't see the particular practice area that pertains to your case, don't hesitate to reach out and schedule a consultation to see if we can help
Most side effects are mild to moderate and tend to show up early on, especially when the dose is increased
Theres currently no cure for PCOS, but losing weight can help with its symptoms